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private sector respectively in Germany and on the Medicare physician fee schedule
in USA. In USA is very difficult to analyze physician’s cost of production. In Spain
regional outpatient tariffs are used as resource components without inclusion of
health staff cost.CONCLUSIONS:Cost data availability is limited and varies widely.
An improvement approach might be the creation of national database used as
reference for cost assessment.
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OBJECTIVES: During the last decade, with the arrival of new innovative vaccines,
there was a huge increase in the number of papers on economic evaluation of
vaccination programmes. Our study had a 3-fold objective: 1) Appraise available
methodological papers dealing with specificities of vaccines in term of health eco-
nomics; 2) Illustrate the impact of each issue in term of decision-making process
with concrete examples; and 3) Identify futures challenges. METHODS: A compre-
hensive literature search was conducted to identify methodological papers dealing
with specificities of economic evaluations of vaccines. Each issue was illustrated
with concrete examples of cost-effectiveness analyses recently performed for HPV
vaccines, or pneumococcal diseases. RESULTS: Except guidelines issued in 2008 by
the WHO and a few general papers, most of methodological papers focused on
modelling techniques and showed a trend in using more and more sophisticated
methods (e.g. calibration). Several papers highlighted the need for having strong
dynamic transmission models of infectious diseases to evaluate appropriately the
cost-effectiveness of vaccination programmes. Other papers focused on the issue
of discounting, and showed the extreme impact of discounting for some vaccines
given this long-term assessment, possibly warranting an alternative method of
discounting for vaccines. Fewer papers highlighted the different type of clinical
evidence compared with curative pharmaceutical drugs, in particular the need to
model immunological responses into clinical endpoints of disease and short-term
efficacy into long-term effectiveness. Although there is an increasing level of ex-
pertise in the field, other important issues such as the choice of realistic assump-
tions (coverage rates or vaccine prices) and the inclusion of externalities (i.e.
changes in the epidemiology of the infection) are not well analysed.
CONCLUSIONS: It is important for decision makers to keep in mind the above
vaccine specificities when they assess the cost-effectiveness of new vaccination
programmes in order to provide relevant conclusions.
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Increase in accessibility and affordability of health care services have been consid-
ered as important policy objectives since the beginning 1980s in Iran. However,
current 60- 70% out-of-pocket payments creates a barrier to an equal access to
quality health services especially in terms of new medicines. This affects equity
issues and consequently the “health” in Iran. Currently, the quasi-government
health insurance organizations considered as main budget holders or purchasers
of medicines and health care services, do not consider comprehensive economic
evaluations (Cost-effectiveness plus Budget impact analyses) for their reimburse-
ment decisions. The present study is introducing a standard Budget Impact Anal-
yses (BIAs) model for the first time in Iran. The main purpose is providing the health
care budget decision makers with a practical tool improving resource allocation as
well as accelerating and facilitating the process of pharmaceutical reimbursement
decision making to address the problem of considerable out-of-pocket payments in
Iran. In the current study, A literature systematic review was conducted on the
international database pubmed to find: 1) Standard guidelines published for BIAs
and 2) Empirical studies doing Pharmaceutical BIAs, published in English language
since Jan 2000 to Dec 2011. Four international standard guidelines and 22 empirical
studies on BIAs were reviewed to provide a comprehensive standard model for
conducting BIAs. They also include practical examples for theoretical recommen-
dations. Moreover, semi-structured interviews were also conducted to ask policy
makers opinions about the necessity of doing BIAs in Iran‘s health care financing
system as well as their opinions about the different parts of the proposed model.
The final model consists of general and detailed recommendations which were
extracted mainly from ISPOR task force report on Principles of Good Practice for
BIAs and other reviewed guidelines. There also were recommendations made by
Iranian policy makers which make the model much more practical for conducting
standard BIAs in Iran.
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OBJECTIVES: Many individuals with long-term care needs rely on informal care to
support them in their daily living. Although public authorities tend to see informal
care as free, caring imposes significant costs on caregivers. However, measuring
and valuing informal care remains a challenge partly due to the absence of clear
guidelines on the topic and partly due to the lack of consensus among economists
on the best methods to use. This review describes the methods used to measure
and monetarily value informal care and discusses their advantages and
limitations. METHODS: Review of: 1) the methods available to measure time; 2)
methods available to value informal care time; and 3) application in published
economic evaluations. RESULTS: Only the diary and the recall methods have been
used in cost-effectiveness analysis, although direct observation and experience
sampling may provide more accurate estimates of time use. The traditional meth-
ods to value time are the opportunity cost, proxy good and contingent valuation
methods. Recently, the well-being method and applications of conjoint analysis to
informal care have been developed. The value of informal care varies widely de-
pending on the methods used. CONCLUSIONS: Informal care should not be viewed
as costless or free since the time inputs into informal care generate costs borne by
the caregiver and society as a whole. Failure to consider informal care may affect
reimbursement decisions and shift costs to patients and their families. The mon-
etary value of informal care can be estimated using existing methods. The clear
advantage of using monetary methods is that results can potentially be included in
cost side of any type of economic evaluations. However, different methods give
different answers both in terms of time-use data and value of informal care. Clear
guidelines are needed on the preferred methods to measure and value informal
care time.
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OBJECTIVES: To assess the validity of cost calculation from incomplete data col-
lection and point out its consequence on bias and on precision of study results.
METHODS:Over a one-year period resource use data from 234 elderly patients with
myocardial infarction were collected quarterly. Applying unit costs, costs for each
quarter were estimated. To examine different strategies of incomplete data collec-
tion, two different methods (inter-/extrapolation) with three different time frames
(omitting quarter two and/or three) were applied and compared with complete
data collection. Sample size was recalculated in response to the variation of cost
estimates due to incomplete data collection. RESULTS: Sum of cost estimation
from complete and incomplete data collection in the case of omitting information
of quarter two or three showed no significant difference. When the time sampling
included only 50% of the full information (omitting quarter two and three) costs
were significantly lower by 3.9% (extrapolation) and 4.6% (interpolation). Generally,
an increase in the standard deviation by 1% leads to an increase in sample size by
2% in the case of a single outcome. Thus, based on observed increased standard
deviation due to incomplete cost collection a larger sample size by about 3% would
be required. This would be efficient, since more time is saved due to incomplete
data collection than extra time is required for additional patients. CONCLUSIONS:
In economic evaluation, cost data can be collected efficiently by reducing fre-
quency of data collection. This can be achieved by data collection for shorter peri-
ods (incomplete data collection) or extending recall windows (complete data col-
lection). When applying the method of incomplete data collection, sample size
calculation has to be modified due to increased standard deviation. This approach
is suitable to enable economic evaluation with lower costs to both study partici-
pants and investigators.
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) devel-
oped—in a consultation process with an international expert panel—the efficiency
frontier (EF) approach to satisfy the legal requirements for economic evaluation in
Germany’s statutory health insurance system. Here we evaluate established tools
for assessing and communicating uncertainty in terms of their applicability to the
EF approach and, where necessary, suggest adjustments to them.METHODS: Tools
to dasplay uncertainty were applied to the EF approach with a simulated data set.
The tools are (i) displays of overall uncertainty (scatter plots, confidence bands,
contour plots); (ii) displays of uncertainty around the reimbursable price (confi-
dence intervals, a modified cost effectiveness acceptability curve, the net health/
monetary benefit approach), and (iii) the ANCOVA approach. RESULTS: We found
that, within the EF approach, the substantial implications of most tools was not
always easy to interpret. Hence, we propose the use of price reimbursement ac-
ceptability curves or the net health benefit approach. CONCLUSIONS: This closes a
gap for handling uncertainty in the economic evaluation approach of the IQWiG
methods. However, the role of statistical testing in determining reimbursable
prices is yet to be defined.
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OBJECTIVES: Consideration of the value presented to the health service by a new
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medical device, whilst crucial for late-stage reimbursement decisions, is often ne-
glected by developers early on due to lack of data. The headroom method has been
proposed as a way to integrate economic evaluation into early go/no-go decisions.
By estimating the maximum reimbursable price (MRP) for a new device idea and
comparing this with forecasted developer’s costs, R&D resources can be chan-
nelled toward innovations for which future returns appear feasible. The aim of this
study was to evaluate the method by applying it retrospectively to a large and
diverse set of case studies, and comparing predicted ‘headroom’ with actual mar-
ket success, within the UK setting. METHODS: The method was applied systemat-
ically to twenty devices/diagnostics invented in the past, retrieved from the UK
national horizon scanning centre (NHSC)’s 2000-2009 database; literature searches
were date restricted to mimic the information available at the ‘concept stage’ of
development. Each case study was followed up to observe the product’s actual
market success or failure compared with the estimated ‘headroom’ and the devel-
opment decision this would have engendered, in order to explore the method’s
predictive value. RESULTS: Headroom correlated with subsequent market success
in 85% of cases. Headroom is most easily elicited where the change proposition of
the innovation is straightforward (e.g. direct replacement technologies); diagnostic
equipment posed particular difficulties. When the numerical headroom assess-
ments were considered alongside unquantifiable factors identified relating to the
clinical and market context, the method offered a good indication of future market
potential. CONCLUSIONS: Despite the strong advocacy of early economic evalua-
tion, the literature lacks a critical appraisal of any such method. This study for the
first time explores the potential implications of basing development decisions on
the headroom method, thereby assessing its potential value to stakeholders.
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Nurse-led self-help treatments for people with chronic fatigue syndrome/myalgic
encephalitis (CFS/ME) have been shown to be effective in reducing fatigue but their
cost-effectiveness is unknown. OBJECTIVES: To determine the cost-effectiveness
of alternative treatment options for people with CFS/ME in a primary care setting.
Design and setting Cost-effectiveness analysis conducted alongside a single blind
randomised controlled trial comparing pragmatic rehabilitation (PR) and support-
ive listening (SL) delivered by primary care nurses, and treatment as usual (TAU)
delivered by the general practitioner (GP) in North West England. METHODS: A
total of 296 patients aged 18 and over with CFS/ME diagnosed using the Oxford
criteria. A within trial analysis was conducted comparing the costs and quality
adjusted life years (QALYs) measured within the time frame of the trial. RESULTS:
Treatment as usual is less expensive and leads to better patient outcomes com-
pared with Supportive Listening. Treatment as usual is also less expensive than
Pragmatic Rehabilitation. PR was effective at reducing fatigue in the short term, but
the impact of the intervention on QALYs was uncertain. However, based on the
results of this trial, PR is unlikely to be cost-effective in this patient population.
CONCLUSIONS: This analysis does not support the introduction of SL. Any benefits
generated by PR are unlikely to be of sufficient magnitude to warrant recommend-
ing PR for this patient group on cost-effectiveness grounds alone. However, dissat-
isfaction with current treatment options means simply continuing with ‘treatment
as usual’ in primary care is unlikely to be acceptable to patients and practitioners.
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OBJECTIVES: To review published methods for estimating expected lifetime costs
in presence of censoring, to compare results with different methods and offer
suggestions for use in future research. METHODS: We searched the literature for
published methods for analysing cost data in presence of censoring. Methods were
assessed and compared with Monte-Carlo simulation using a hypothetical dataset,
introducing various degrees of censoring. All calculations were performed in
STATA 11.2. RESULTS: Different methods have been proposed to estimate lifetime
costs in presence of censoring. In the most commonly used methods, time is di-
vided into periods, the mean cost is estimated for each period and expected costs
estimated as a weighted sum across periods. However, the task of determining the
period length is normally left to the analyst. If time periods are too long informa-
tion risks being lost, while very short but frequent periods impedes calculation
speed. An alternative approach is proposed, which avoids the arbitrary choice of
period length. CONCLUSIONS: Expected lifetime costs can be estimated through a
weighted sum of all observed costs, with weights constructed by the Kaplan-Meier
survival probability and the number of patients at risk at the time each cost was
incurred. This avoids constructing time periods with arbitrary length and poten-
tially improves calculation speed or accuracy.
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OBJECTIVES:Thereexistsvery little inthewayofcurrentguidelinesor literatureastothe
combination and sequence of visualisation technologies (invasive or non-invasive) that
should be used for the visualisation of seizure focus in patients with refractory epilepsy
being considered for surgery. This lack of guidelines is typical in many diagnostic technol-
ogies. This study seeks to both create an explanatory analytical framework to demon-
strate the variety of technologies, sequences and combinations available before epilepsy
surgery is conducted, as well as focussing on the more general questions of the difficulties
associated with the evaluation of diagnostic technologies and consider the role of meth-
ods to characterise uncertainty in economic evaluations. METHODS: The decision an-
alytical framework consisted of three different potential strategies that could be
employed in order to elicit the most accurate information given an appropriate
cost-effectiveness threshold. This framework was used to consider the wider dif-
ficulties and sensitivities of the analysis of diagnostic technologies in combination.
RESULTS: The analytical framework section of this study found that (assuming an
initial MRI and video-EEG) a strategy of FDG-PET being the first test being per-
formed, followed by invasive EEG if the result of the test does not lead to a clear
decision on whether the patient should proceed to surgery was optimal.
CONCLUSIONS: In a general context, we found that in the evaluation of combina-
tions of diagnostic technologies it is important not only to consider the added value
of each individual test but also the correct combination and order in which the tests
are employed. In addition the evaluation of diagnostics will always be highly sen-
sitive to the cost-effectiveness of the subsequent treatment.
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OBJECTIVES: There is limited information associating CHA2DS2VASc and ATRIA scores
among patients newly prescribed an anticoagulant and stroke/systemic embolism (Sys-
Emb) and bleeding event rates in the real-world.METHODS:A retrospective analysis of
a de-identified, pharmacy-medical claims database was conducted in patients with
atrial fibrillation (AFIB) and new to dabigatran or warfarin (no drug 6-months prior)
from 1/1/10-2/28/11. Patients had continuous eligibility of 12 months prior to and 4
months post initial anticoagulation claim date. Patients’ CHA2DS2VASc, and
ATRIA risk scores were determined using demographic data and ICD-9/CPT codes
(2 separate dates) in the prior 12 months. Stroke/SysEmb risk was classified by
CHA2DS2VASc score as: low-risk0-1, moderate-risk2, and high-risk 2. Bleed-
ing risk using ATRIA score was classified as: low-risk0-3, moderate-risk4, and
high-risk 5. Stroke/SysEmb and bleeding events rates/100 patient years were
based on ICD-9 codes in the 4 months post anticoagulant initiation. RESULTS: A
total of 8,162 patients (warfarin7,072 and dabigatran1,090) were analyzed:
age7511 years (82%65 years); 57% were male; with a CHA2DS2VASc and ATRIA
risk scores of 3.81.7 and 2.81.9, respectively. At 4 months, Stroke/SysEmb and
overall bleeding event rates were 5.9% (95%CI 5.4% - 6.4%) and 11.1% (95%CI 10.4%
- 11.8%) respectively. As CHA2DS2VASc or ATRIA scores increased, so did the rates
for Stroke/SysEmb or bleeding events: Stroke/SysEmb low-risk: 0.88% (95%CI 0.18%
- 1.58%), moderate-risk: 1.76% (95%CI 0.95% - 2.57%) and high-risk: 7.05% (95%CI
6.43% - 7.67%); bleeding by ATRIA, low-risk: 8.62% (95%CI 7.93% - 9.31%), moderate-
risk: 16.79% (95%CI 14.15% - 19.43%) and high-risk: 21.69% (95%CI 19.21% - 24.17%).
CONCLUSIONS: Increasing CHA2DS2VASc and ATRIA scores were associated with
greater rates of Stroke/SysEmb or bleeding events in this real-world, anticoagulant-
treated population. Using claims-based CHA2DS2VASc and ATRIA scoring as a
screening tool may identify patients at risk of thromboembolic and bleeding events
when initiating anticoagulation therapy.
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OBJECTIVES: Real-world data sources (RWD) provide an important means for as-
sessing the real clinical outcomes and value of newly marketed drugs. We aimed to
develop a methodology to ascertain the feasibility of RWD in Europe to evaluate the
effectiveness of new anti-diabetic drugs. METHODS: We searched a proprietary
database of European RWDs and publicly available RWD initiatives (including
TRANSFoRm and ISPOR international digest of databases). Additional RWDs were
identified by literature search with PubMed and Google. A scoring algorithm was
developed to prioritize RWDs on the basis of availability of relevant attributes. Each
of 11 attributes was scored on a scale depending on the data to be captured and
weighted based on the attribute’s importance. According to our scoring algorithm,
a database could achieve a maximum of 70 points and a minimum of 50 points to
be sufficient for evaluating effectiveness. RESULTS: We identified 42 RWDs with
the potential for evaluating the effectiveness of anti-diabetic drugs and selected 25
for scoring after obtaining additional information. The scoring algorithm allowed
us to prioritise RWDs based on 3 key attributes: 1) number of patients prescribed
the drugs; 2) completeness of data for key parameters for which effectiveness was
to be evaluated (e.g. lab and biometric values); 3) non-parameter attributes (country
scope, ability to link to other RWDs, access and cost ). The algorithm yielded 16
RWDs meeting the predefined threshold of 50 points for evaluating effectiveness.
However, further assessment indicated low feasibility of the 16 RWDs without
linkage. CONCLUSIONS: We developed a unique and systematic approach to eval-
uating European RWDs; however, the main limitation of our methodology was the
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